Scientific Papers

Alcohol increases treatment failure for Helicobacter pylori eradication in Asian populations | BMC Gastroenterology


  • Song C, Qian X, Zhu Y, et al. Effectiveness and safety of furazolidone-containing quadruple regimens in patients with Helicobacter pylori infection in real-world practice. Helicobacter. 2019;24: e12591.

    Article 
    PubMed 

    Google Scholar
     

  • Takara Y, Endo H, Nakano R, et al. Smoking and Drinking Did Not Increase the Failure of Therapeutic Helicobacter pylori Eradication by Vonoprazan, Clarithromycin, and Amoxicillin. Digestion. 2019;99:172–8.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Eto H, Suzuki S, Kusano C, et al. Impact of body size on first-line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy. Helicobacter. 2021;26: e12788.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Malfertheiner P, Megraud F, O’Morain CA, et al. European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6–30.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Suzuki S, Esaki M, Kusano C, Ikehara H, Gotoda T. Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance? World J Gastroenterol. 2019;25:1907–12.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Shah SC, Iyer PG, Moss SF. AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review. Gastroenterology. 2021;160:1831–41.

    Article 
    PubMed 

    Google Scholar
     

  • Yao CC, Kuo CM, Hsu CN, et al. First-line Helicobacter pylori eradication rates are significantly lower in patients with than those without type 2 diabetes mellitus. Infect Drug Resist. 2019;29:1425–31.

    Article 

    Google Scholar
     

  • Manes G, Pieramico O, Perri F, et al. Twice-daily standard dose of omeprazole achieves the necessary level of acid inhibition for Helicobacter pylori eradication. A randomized controlled trial using standard and double doses of omeprazole in triple therapy. Dig Dis Sci. 2005;50:443–8.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Yu J, Yang P, Qin X, Li C, Lv Y, Wang X. Impact of smoking on the eradication of Helicobacter pylori. Helicobacter. 2022;27:e12860.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Furuta T, Sagehashi Y, Shirai N, Sugimoto M, Nakamura A, Kodaira M, Kenmotsu K, Nagano M, Egashira T, Ueda K, et al. Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection. Clin Gastroenterol Hepatol. 2005;3:564–73.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Pan KF, Zhang L, Gerhard M, et al. A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication. Gut. 2016;65:9–18.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Zhang YW, Hu WL, Cai Y, et al. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication. World J Gastroenterol. 2018;24:4596–605.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Yi DM, Yang TT, Chao SH, et al. Comparison the cost-efficacy of furazolidone-based versus clarithromycin-based quadruple therapy in initial treatment of Helicobacter pylori infection in a variable clarithromycin drug-resistant region, a single-center, prospective, randomized, open-label study. Medicine (Baltimore). 2019;98: e14408.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Cutler AF, Schubert TT. Patient factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol. 1993;88:505–9.

    CAS 
    PubMed 

    Google Scholar
     

  • Silva FM, Zaterka S, Eisig JN, Chehter EZ, Chinzon D, Laudanna AA. Factors affecting Helicobacter pylori eradication using a seven-day triple therapy with a proton pump inhibitor, tinidazole and clarithromycin, in Brazilian patients with peptic ulcer. Rev Hosp Clin Fac Med Sao Paulo. 2001;56:11–6.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Okubo H, Akiyama J, Kobayakawa M, et al. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility. J Gastroenterol. 2020;55:1054–61.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Noda H, Noguchi S, Yoshimine T, et al. A Novel Potassium-Competitive Acid Blocker Improves the Efficacy of Clarithromycin-containing 7-day Triple Therapy against Helicobacter pylori. J Gastrointestin Liver Dis. 2016;25:283–8.

    Article 
    PubMed 

    Google Scholar
     

  • Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Labenz J, Leverkus F, Börsch G. Omeprazole plus amoxicillin for cure of Helicobacter pylori infection. Factors influencing the treatment success. Scand J Gastroenterol. 1994;29:1070–5.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Hazell SL, Daskalopoulous G, Mitchell HM, Massey D. Lansoprazole and amoxycillin: observations on the treatment of Helicobacter pylori infection. J Gastroenterol Hepatol. 1997;12:93–9.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Olafsson S, Berstad A, Bang CJ, et al. Spiramycin is comparable to oxytetracycline in eradicating H. pylori when given with ranitidine bismuth citrate and metronidazole. Aliment Pharmacol Ther. 1999;13:651–9.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Kamada T, Haruma K, Komoto K, et al. Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin. Helicobacter. 1999;4:204–10.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Fallone CA, Barkun AN, Friedman G, et al. Is Helicobacter pylori eradication associated with gastroesophageal reflux disease? Am J Gastroenterol. 2000;95:914–20.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Perri F, Villani MR, Festa V, Quitadamo M, Andriulli A. Predictors of failure of Helicobacter pylori eradication with the standard “Maastricht triple therapy.” Aliment Pharmacol Ther. 2001;15:1023–9.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Maconi G, Parente F, Russo A, Vago L, Imbesi V, Bianchi PG. Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? Am J Gastroenterol. 2001;96:359–66.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Mantzaris GJ, Petraki K, Archavlis E, et al. Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study. Eur J Gastroenterol Hepatol. 2002;14:1237–43.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Queiroz DM, Dani R, Silva LD, et al. Factors associated with treatment failure of Helicobacter pylori infection in a developing country. J Clin Gastroenterol. 2002;35:315–20.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Baena JM, López C, Hidalgo A, et al. Relation between alcohol consumption and the success of Helicobacter pylori eradication therapy using omeprazole, clarithromycin and amoxicillin for 1 week. Eur J Gastroenterol Hepatol. 2002;14:291–6.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Broutet N, Tchamgoué S, Pereira E, Lamouliatte H, Salamon R, Mégraud F. Risk factors for failure of Helicobacter pylori therapy–results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther. 2003;17:99–109.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Ishioka H, Mizuno M, Take S, et al. A better cure rate with 800 mg than with 400 mg clarithromycin regimens in one-week triple therapy for Helicobacter pylori infection in cigarette-smoking peptic ulcer patients. Digestion. 2007;75:63–8.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Namiot DB, Leszczyńska K, Namiot Z, Kurylonek AJ, Kemona A. Smoking and drinking habits are important predictors of Helicobacter pylori eradication. Adv Med Sci. 2008;53:310–5.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Singh N, Deb R, Kashyap PC, Bhatia V, Ahuja V, Sharma MP. Body mass index and per capita income influence duodenal ulcer healing and H. pylori eradication whilst dietary factors play no part. Trop Gastroenterol. 2008;29:26–31.

    PubMed 

    Google Scholar
     

  • Gatta L, Di Mario F, Vaira D, et al. Helicobacter pylori eradication: are we really all equal? A controlled study in native and immigrant population. Intern Emerg Med. 2011;6:35–9.

    Article 
    PubMed 

    Google Scholar
     

  • Lim JH, Lee DH, Lee ST, et al. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection. World J Gastroenterol. 2015;21:13124–31.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kim SE, Park MI, Park SJ, et al. Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy. Korean J Intern Med. 2015;30:801–7.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Tsai CE, Liang CM, Lee CH, et al. First-line Helicobacter pylori eradication among patients with chronic liver diseases in Taiwan. Kaohsiung J Med Sci. 2016;32:397–402.

    Article 
    PubMed 

    Google Scholar
     

  • Huh CW, Youn YH, da Jung H, Park JJ, Kim JH, Park H. Early Attempts to Eradicate Helicobacter pylori after Endoscopic Resection of Gastric Neoplasm Significantly Improve Eradication Success Rates. PLoS ONE. 2016;11:e0162258.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ahn HJ, Kim DP, Chu MS, et al. Efficacy and Safety of the Triple Therapy Containing Ilaprazole, Levofloxacin, and Amoxicillin as First-Line Treatment in Helicobacter pylori Infections. Gastroenterol Res Pract. 2017;2017:1654907.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Chang YW, Ko WJ, Oh CH, et al. Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis. Korean J Intern Med. 2019;34:1022–9.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Jin Y, Zhang S, Pan J, et al. Comparison of efficacy and safety of ilaprazole and esomeprazole both in initial treatment regimen and retreatment regimen of Helicobacter pylori infection in chronic gastritis. Pharmazie. 2019;74:432–8.

    CAS 
    PubMed 

    Google Scholar
     

  • Ozeki K, Asano M, Furuta T, Ojima T. Relationship between primary eradication of Helicobacter pylori and drinking habits in women: collaborative research between a pharmacy and a clinic. Epidemiol Infect. 2019;147: e292.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Nkuize M, Vanderpas J, Buset M, Delforge M, Cadière GB, De Wit S. Failure to eradicate Helicobacter pylori infection is more frequent among HIV-positive patients. HIV Med. 2021;22:547–56.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Lin CK, Hsu PI, Lai KH, et al. One-week quadruple therapy is an effective salvage regimen for Helicobacter pylori infection in patients after failure of standard triple therapy. J Clin Gastroenterol. 2002;34:547–51.

    Article 
    PubMed 

    Google Scholar
     

  • Hsu PI, Lai KH, Lin CK, et al. A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. Am J Gastroenterol. 2005;100:2387–92.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Lee JY, Kim N, Kim MS, et al. Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. Dig Dis Sci. 2014;59:1235–43.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Kasai T, Suzuki S, Kusano C, et al. High Body Mass Index Is Correlated with the Success of Vonoprazan-Based Second-Line Therapy for Helicobacter Pylori Infection. Tohoku J Exp Med. 2021;253:85–94.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Morasso MI, Hip A, Márquez M, González C, Arancibia A. Amoxicillin kinetics and ethanol ingestion. Int J Clin Pharmacol Ther Toxicol. 1988;26:428–31.

    CAS 
    PubMed 

    Google Scholar
     

  • Theile D, Schmidt TT, Haefeli WE, Weiss J. In-vitro evaluation of chronic alcohol effects on expression of drug-metabolizing and drug-transporting proteins. J Pharm Pharmacol. 2013;65:1518–25.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Takeuchi F, Isono M, Nabika T, et al. Confirmation of ALDH2 as a Major locus of drinking behavior and of its variants regulating multiple metabolic phenotypes in a Japanese population. Circ J. 2011;75:911–8.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Goedde HW, Agarwal DP, Harada S, et al. Population genetic studies on aldehyde dehydrogenase isozyme deficiency and alcohol sensitivity. Am J Hum Genet. 1983;35:769–72.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92:6–10.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Cederbaum AI. Alcohol metabolism. Clin Liver Dis. 2012;16:667–85.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kato M, Ota H, Okuda M, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition. Helicobacter. 2019;24:e12597.

    Article 
    PubMed 

    Google Scholar
     

  • Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ, GRADE Working Group. What is “quality of evidence” and why is it important to clinicians? BMJ. 2008;336:995–8.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Weisse ME, Eberly B, Person DA. Wine as a digestive aid: comparative antimicrobial effects of bismuth salicylate and red and white wine. BMJ. 1995;311:1657–60.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Marimón JM, Bujanda L, Gutiérrez-Stampa MA, Cosme A, Arenas JI. In vitro bactericidal effect of wine against Helicobacter pylori. Am J Gastroenterol. 1998;93:1392.

    Article 
    PubMed 

    Google Scholar
     



  • Source link